EQS-News

Bayer and Evotec collaborate to advance precision cardiology

EQS-News: Evotec SE / Key word(s): Miscellaneous Bayer and Evotec collaborate to advance precision cardiology 30.04.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY

Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs).

The collaboration aims to identify and validate novel targets, with the goal of building a portfolio of precision cardiology therapeutics by leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs). iPSCs provide unique opportunities to identify new disease mechanisms and pathways for novel treatments.

Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms for the development of innovative treatment options.

“This development takes our long-standing collaboration with Evotec to a new level, and has the added benefit of lessons learned from working together the past 12 years,” said Juergen Eckhardt, M.D., Head of Business Development & Licensing at Bayer’s Pharmaceuticals Division. “We remain committed to develop innovative therapies for patients in need and to tackle the high burden of cardiovascular disease.”

“Cardiovascular diseases are the leading cause of death globally,” said Dr Christian Rommel, Head of Research and Development at Bayer’s Pharmaceuticals Division. “The refocused collaboration will leverage Evotec's industrialised iPSC-based disease modelling platform and Bayer’s leadership in cardiology to advance a portfolio of innovative therapies for cardiovascular diseases with high unmet medical need. This complements our focus on disease areas where we can truly improve the standard of care by delivering superior therapeutic solutions to patients in need.”